AbbVie Inc. (ABBV)
USD 176.72
(1.69%)
USD 176.72
(1.69%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 4.09 Billion USD | 14.53% |
| 2022 | 3.57 Billion USD | 14.42% |
| 2021 | 3.12 Billion USD | -5.5% |
| 2020 | 3.31 Billion USD | 82.57% |
| 2019 | 1.81 Billion USD | 12.96% |
| 2018 | 1.6 Billion USD | 0.0% |
| 2017 | 1.6 Billion USD | 11.15% |
| 2016 | 1.44 Billion USD | -16.0% |
| 2015 | 1.71 Billion USD | 52.94% |
| 2014 | 1.12 Billion USD | -2.26% |
| 2013 | 1.15 Billion USD | 5.41% |
| 2012 | 1.09 Billion USD | 25.17% |
| 2011 | 871.58 Million USD | 4.22% |
| 2010 | 836.27 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 4.21 Billion USD | -0.64% |
| 2024 Q1 | 4.24 Billion USD | 3.56% |
| 2024 Q3 | 4.45 Billion USD | 5.5% |
| 2023 Q1 | 3.83 Billion USD | 7.1% |
| 2023 Q2 | 4.05 Billion USD | 5.79% |
| 2023 FY | 4.09 Billion USD | 14.53% |
| 2023 Q3 | 3.98 Billion USD | -1.82% |
| 2023 Q4 | 4.09 Billion USD | 2.96% |
| 2022 Q2 | 3.39 Billion USD | -2.5% |
| 2022 FY | 3.57 Billion USD | 14.42% |
| 2022 Q4 | 3.57 Billion USD | 12.83% |
| 2022 Q3 | 3.17 Billion USD | -6.6% |
| 2022 Q1 | 3.48 Billion USD | 11.35% |
| 2021 Q1 | 3.27 Billion USD | -1.15% |
| 2021 FY | 3.12 Billion USD | -5.5% |
| 2021 Q2 | 3.38 Billion USD | 3.48% |
| 2021 Q3 | 3.09 Billion USD | -8.62% |
| 2021 Q4 | 3.12 Billion USD | 1.1% |
| 2020 Q2 | 4.05 Billion USD | 120.12% |
| 2020 Q3 | 3.47 Billion USD | -14.41% |
| 2020 Q4 | 3.31 Billion USD | -4.72% |
| 2020 FY | 3.31 Billion USD | 82.57% |
| 2020 Q1 | 1.84 Billion USD | 1.71% |
| 2019 Q2 | 1.89 Billion USD | 11.34% |
| 2019 Q4 | 1.81 Billion USD | -6.01% |
| 2019 FY | 1.81 Billion USD | 12.96% |
| 2019 Q1 | 1.7 Billion USD | 6.04% |
| 2019 Q3 | 1.92 Billion USD | 1.79% |
| 2018 Q2 | 1.58 Billion USD | -9.09% |
| 2018 FY | 1.6 Billion USD | 0.0% |
| 2018 Q4 | 1.6 Billion USD | -10.13% |
| 2018 Q3 | 1.78 Billion USD | 13.04% |
| 2018 Q1 | 1.73 Billion USD | 8.29% |
| 2017 Q3 | 1.78 Billion USD | 12.83% |
| 2017 Q4 | 1.6 Billion USD | -10.08% |
| 2017 Q1 | 1.42 Billion USD | -1.18% |
| 2017 Q2 | 1.58 Billion USD | 10.86% |
| 2017 FY | 1.6 Billion USD | 11.15% |
| 2016 Q1 | 1.78 Billion USD | 4.07% |
| 2016 FY | 1.44 Billion USD | -16.0% |
| 2016 Q3 | 1.63 Billion USD | -7.18% |
| 2016 Q4 | 1.44 Billion USD | -11.41% |
| 2016 Q2 | 1.75 Billion USD | -1.84% |
| 2015 Q2 | 1.62 Billion USD | 58.81% |
| 2015 FY | 1.71 Billion USD | 52.94% |
| 2015 Q1 | 1.02 Billion USD | -9.07% |
| 2015 Q4 | 1.71 Billion USD | -6.63% |
| 2015 Q3 | 1.84 Billion USD | 13.43% |
| 2014 Q3 | 1 Billion USD | -3.82% |
| 2014 Q4 | 1.12 Billion USD | 11.51% |
| 2014 Q2 | 1.04 Billion USD | -5.07% |
| 2014 Q1 | 1.1 Billion USD | -4.0% |
| 2014 FY | 1.12 Billion USD | -2.26% |
| 2013 FY | 1.15 Billion USD | 5.41% |
| 2013 Q1 | 1.03 Billion USD | -4.95% |
| 2013 Q2 | 1.08 Billion USD | 4.63% |
| 2013 Q3 | 1.17 Billion USD | 8.02% |
| 2013 Q4 | 1.15 Billion USD | -1.88% |
| 2012 FY | 1.09 Billion USD | 25.17% |
| 2012 Q4 | 1.09 Billion USD | 13.78% |
| 2012 Q3 | 958.87 Million USD | 11.14% |
| 2012 Q2 | 862.77 Million USD | -5.79% |
| 2012 Q1 | 915.79 Million USD | 5.07% |
| 2011 FY | 871.58 Million USD | 4.22% |
| 2011 Q4 | 871.58 Million USD | 0.0% |
| 2010 FY | 836.27 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Bristol-Myers Squibb Company | 2.66 Billion USD | -53.982% |
| Bristol-Myers Squibb Company Ce | 2.66 Billion USD | -53.982% |
| Johnson & Johnson | 11.18 Billion USD | 63.34% |
| Eli Lilly and Company | 5.77 Billion USD | 28.995% |
| Merck & Co., Inc. | 6.35 Billion USD | 35.53% |
| Novartis AG | 5.91 Billion USD | 30.678% |
| Organon & Co. | 1.31 Billion USD | -211.711% |
| Pfizer Inc. | 10.18 Billion USD | 59.77% |